ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

raludotatug deruxtecan

Also written as “R-DXd”, “Raludotatug Deruxtecan” and “DS-6000a”.

In Merck’s pipeline, Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi. Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms · Fallopian Tube Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 2 companies.

Drug pageRaludotatug deruxtecan: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 29, 202611 company-led studies, 11 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck77 open or runningphase 3since Jul 29, 2026Jun 21, 2021Mar 27, 2029phase 2 · NCT06843447
Daiichi Sankyoits history only44 open or runningphase 3since Nov 27, 2023Dec 16, 2020Dec 30, 2026phase 1 · NCT04707248
  • Named in Merck’s own pipeline as raludotatug deruxtecan (MK-5909), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 21, 2021First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT04938817 · 110 enrolled · United States, Australia, Austria and more
  2. Jul 21, 2022Named raludotatug deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 127
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. Jan 13, 20252 phase 2 studiesNCT06780098, NCT06780085
  5. Feb 20, 2025Phase 2 study in Ovarian Cancer RecurrentNCT06843447 · 605 planned · United States, Australia, Canada and more
  6. Mar 3, 2025Phase 2 study in Gastrointestinal NeoplasmsNCT06864169 · 160 enrolled · United States, Argentina, Canada and more
  7. Jul 29, 2026Phase 3 study in Ovarian NeoplasmsPhase 3 reachedNCT07743164 · 646 planned · United States, China, Israel and more
  8. Aug 17, 2026Phase 3 study in Ovarian NeoplasmsNCT07776691 · 802 planned · United States, Israel, South Korea and more

Ahead

  1. Mar 27, 2029Primary completion: phase 2 study in Ovarian Cancer RecurrentNCT06843447
  2. Dec 10, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT04938817
  3. Aug 31, 2031Primary completion: phase 3 study in Ovarian NeoplasmsNCT07743164
  4. Mar 2, 2032Primary completion: phase 2 study in Lung NeoplasmsNCT06780098

TargetBeta

“Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) ”NCIt, by rule

Other programs on CDH6

ProgramCompanyFurthest phaseStudies
TJ102rulephrontline-biopharmaphase 21
Anti-CDH6 Antibody-drug Conjugate SIM0505rulenextcure-incphase 11

Studies

All 7 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07776691Ovarian Neoplasms · United States, Israel, South Korea and more3RecruitingMar 19, 2032802
NCT07743164Ovarian Neoplasms · United States, China, Israel and more3RecruitingAug 31, 2031646
NCT06864169Gastrointestinal Neoplasms · United States, Argentina, Canada and more2Active, not recruitingAug 18, 2026160
NCT06843447Ovarian Cancer Recurrent · United States, Australia, Canada and more2RecruitingMar 27, 2029605
NCT06780098Lung Neoplasms · United States, Chile, China and more2RecruitingMar 2, 2032144
NCT06780085Carcinoma, Non-Small-Cell Lung · United States, Chile, Germany and more2Active, not recruitingMar 12, 203296
NCT04938817Small Cell Lung Carcinoma · United States, Australia, Austria and more2Active, not recruitingDec 10, 2029110

How it is read

Names in the registry

  • “R-DXd”, 5 entries
  • “Raludotatug Deruxtecan”, 2 entries
  • “DS-6000a”, 2 entries
  • “R-DXD”, 1 entry
  • “Raludotatug deruxtecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.